For the Quarter Ending September 2025
APAC
鈥� In China, the Neomycin Sulphate Price Index rose by 1.5683% quarter-over-quarter, reflecting modest demand improvement.
鈥� The average Neomycin Sulphate price for the quarter was approximately USD 11333.33/MT as reported locally.
鈥� Neomycin Sulphate Spot Price remained stable amid balanced domestic supply and limited export enquiries recently.
鈥� Neomycin Sulphate Price Forecast points to modest upside risks driven by recovering downstream pharmaceutical demand.
鈥� Neomycin Sulphate Production Cost Trend showed slight increases due to higher raw material and utility expenditures.
鈥� Neomycin Sulphate Demand Outlook improved marginally with seasonal procurement by API manufacturers supporting volumes sustainably.
鈥� Neomycin Sulphate Price Index benefited from constrained shipments and steady operating rates at major Chinese producers.
鈥� Inventory and export demand dynamics supported tighter availability, reinforcing short term regional pricing resilience ahead.
Why did the price of Neomycin Sulphate change in September 2025 in APAC?
鈥� Domestic pharmaceutical buying uptick increased consumption, tightening local availability and supporting price resilience during quarter.
鈥� Higher feedstock and energy costs nudged production expenses upward, exerting upward pressure on market pricing.
鈥� Logistics delays and constrained export flows reduced supply flexibility, amplifying Price Index sensitivity to demand changes.
Europe
鈥� In Germany, the Neomycin Sulphate Price Index rose by 1.56% quarter-over-quarter, reflecting modest demand recovery.
鈥� The average Neomycin Sulphate price for the quarter was approximately USD 11415.00/MT, based on CFR Hamburg reported volumes.
鈥� Neomycin Sulphate Spot Price showed limited upside due to steady inventories and subdued regional export demand.
鈥� Neomycin Sulphate Price Forecast indicates range-bound movement near current levels absent major supply disruptions and significant feedstock-driven inflation.
鈥� Neomycin Sulphate Production Cost Trend remains stable as raw material and energy cost pressures were moderate during the quarter.
鈥� Neomycin Sulphate Demand Outlook points to gradual recovery in institutional tendering and pharmaceutical manufacturing activity.
鈥� Elevated operating rates at regional producers supported the Neomycin Sulphate Price Index despite limited spot transaction volumes.
鈥� Logistics constraints and seasonal procurement patterns mildly supported Neomycin Sulphate transactional premiums in northern European markets.
Why did the price of Neomycin Sulphate change in September 2025 in Europe?
鈥� Improved regional demand recovery increased purchasing activity, tightening availability and supporting modest price appreciation recently.
鈥� Feedstock and energy pricing curbed cost escalation, reducing upward pressure on Neomycin Sulphate Price Index
鈥� Logistics delays and selective tendering increased short-term tightness, marginally elevating transactional premiums across Germany markets.
North America
鈥� In USA, the Neomycin Sulphate Price Index rose by 1.62% quarter-over-quarter, driven by export demand.
鈥� The average Neomycin Sulphate price for the quarter was approximately USD 11495.00/MT in North America.
鈥� Neomycin Sulphate Spot Price eased mid-quarter amid softer procurement and cautious short-term buyer behaviour patterns.
鈥� Inventory draws improved late quarter supporting the Neomycin Sulphate Price Index despite narrow producer margins.
鈥� Neomycin Sulphate Production Cost Trend rose slightly as feedstock and energy charges increased regionally overall.
鈥� Neomycin Sulphate Demand Outlook stable with steady pharmaceutical contracts offsetting variable tender volumes at hospitals.
鈥� Neomycin Sulphate Price Forecast suggests modest stability short-term barring unexpected supply disruptions or demand spikes.
鈥� Major producer uptime tempered volatility in the Neomycin Sulphate Price Index and supported export readiness.
Why did the price of Neomycin Sulphate change in September 2025 in North America?
鈥� Export demand firmed late quarter, tightening effective supply and supporting the modest Neomycin Sulphate Price increase.
鈥� Regional feedstock and energy cost pressures lifted production costs, marginally offsetting downward price pressure from inventories.
鈥� Logistics normalization reduced delays but buyer purchasing patterns remained cautious, moderating sharp upside in the Price Index.
For the Quarter Ending March 2025
North America
In Q1 2025, Neomycin Sulphate prices in the U.S. exhibited a three-phase trend鈥攎inor rise in January, stability in February, and a significant decline in March. January's slight price increase was driven by accelerated imports ahead of a 10% tariff on Chinese goods, effective February 4. Importers rushed to stockpile inventory, anticipating higher costs and potential disruptions from a proposed port strike and the Chinese Lunar New Year. Rising energy prices also contributed to marginal operational cost increases, supporting the price uptick.聽
In February, prices stabilized as suppliers effectively managed inventories and logistics improved post-holiday. Despite the tariff taking effect, adequate supply levels and cautious buying ahead of a potential 25% tariff in April helped maintain balance. However, in March, prices fell sharply due to weak downstream demand and buyer hesitancy. With sufficient inventory from earlier stockpiling and growing uncertainty around further tariff escalations, distributors reduced procurement. Suppliers, facing sluggish market activity, offered aggressive discounts to move excess stock.聽
The quarter closed with prices lower than at the start, shaped by short-term supply shocks early on and subdued demand pressures by the end. As of the end of Q1, Neomycin Sulphate was priced at USD 11250 per metric ton.
Asia Pacific
In Q1 2025, Neomycin Sulphate prices in China initially remained stable through January and February, supported by balanced supply and steady demand from pharmaceutical and healthcare sectors. Despite a seasonal slowdown in January ahead of the Lunar New Year, production was largely uninterrupted, and consistent order flows sustained market stability. February saw a smooth post-holiday recovery in manufacturing and logistics, while temporary inventory gaps were quickly addressed. However, in March, the market shifted as prices declined due to oversupply and weakened demand. Manufacturers ramped up production ahead of summer maintenance, leading to surplus stock. Concurrently, subdued post-holiday demand鈥攑artly due to earlier stockpiling鈥攃aused inventories to rise. A stronger yuan discouraged exports, while concerns over rising tariffs and trade tensions further dampened buyer sentiment. Suppliers responded by offering discounts to reduce stock, placing downward pressure on prices. Overall, while Q1 began with stable pricing conditions, March witnessed a clear bearish trend driven by oversupply, cautious buying behavior, and export headwinds. By the end of Q1, Neomycin Sulphate was priced at USD 11100 per metric ton in China.
Europe
Neomycin Sulphate prices in Germany showed a downward trend throughout Q1 2025. In January, prices remained relatively stable with a slight increase, supported by improved business morale and cautious optimism in the pharmaceutical and healthcare sectors. Early restocking driven by concerns over Red Sea shipping diversions and Lunar New Year demand contributed mildly to the price uptick. However, February marked the beginning of a price decline as the Euro鈥檚 strength and sharply reduced ocean freight rates improved import economics. Combined with early stockpiling, these factors led to ample supply and subdued demand amid political and economic uncertainty. The downward momentum continued into March, with persistent oversupply, declining post-holiday demand, and further drops in freight rates reinforcing soft market conditions. Buyers focused on depleting existing inventories rather than initiating new purchases, contributing to weaker pricing. Overall, the quarter was defined by early strength followed by consistent price pressure, shaped by a blend of favorable import conditions, cautious buyer behavior, and muted downstream demand. By the end of Q1, Neomycin Sulphate was priced at USD 11200 per metric ton.聽
For the Quarter Ending December 2024
North America
In Q4 2024, Neomycin Sulphate prices in the USA experienced a downward trend, largely due to economic uncertainty, inflationary pressures, and weakened demand. In October, concerns over inflation and the upcoming presidential election led to reduced consumer confidence, which in turn caused businesses to adopt a more cautious approach. This hesitation, coupled with lower consumer spending and slower corporate investments, resulted in a decline in demand across multiple sectors, prompting companies to reduce prices to remain competitive.
The price decrease continued into November, driven by several interconnected factors. Softer demand from the pharmaceutical and healthcare industries, exacerbated by high interest rates and persistent inflation, made consumers more cautious in their purchasing decisions. Additionally, the US dollar's appreciation against foreign currencies made imports cheaper, ensuring a steady supply of Neomycin Sulphate. The resolution of logistical issues, particularly the ILA strike, facilitated smoother supply chains, allowing suppliers to lower prices further.
In December, Neomycin Sulphate prices stabilized, influenced by a slight drop in US consumer confidence and typical holiday-season demand slowdowns in key end-user sectors. Despite this, proactive inventory buildup ahead of the Chinese Lunar New Year and concerns over potential disruptions helped maintain a balanced market. Rising inflation and uncertainty about proposed tariffs on U.S. imports led to a cautious approach, with only marginal price shifts as market participants opted for a wait-and-see strategy.
Asia Pacific
In Q4 2024, Neomycin Sulphate prices in China experienced notable fluctuations, influenced by shifting domestic and international demand. In October, prices declined due to weak domestic consumption and an oversupply in the market, intensified by competitive pricing strategies among suppliers. External demand also suffered, with geopolitical uncertainties, particularly regarding the U.S. elections and protectionist policies, dampening export orders.
November saw a slight price increase, driven by a surge in factory activity and an uptick in new orders, including from international buyers. Rising raw material costs and the depreciation of the Chinese yuan further supported the price rise, making exports more attractive and fueling demand.
However, December witnessed a decline in prices again, as disinflation in China and subdued demand across sectors, including pharmaceuticals, took a toll. The holiday season reduced foreign orders, particularly from the U.S. and Germany, further weakening demand. In response to excess stock, suppliers reduced prices to remain competitive, leading to an overall price decrease by the end of the year.
Europe
In Q4 2024, Neomycin Sulphate prices in Germany saw a gradual decline, driven by weak demand and economic concerns. In October, prices dropped due to consumer inflation worries, subdued spending, and a 60% decrease in container shipping prices from Asia to Europe. Retailers proactively adjusted logistics, ensuring supply during peak periods, which helped stabilize availability. In November, prices continued their slight decline, with the ongoing downturn in consumer spending in Germany and weak retail performance. A 1.9% drop in energy prices also contributed to lower operational costs, which were passed on to consumers. Despite these factors, inventories remained strong, supporting competitive pricing. In December, prices stabilized with a minor dip. Demand in key sectors like healthcare and pharmaceuticals moderated but remained steady, and suppliers maintained inventories to manage stock effectively. Logistical delays due to winter weather had minimal impact, and the market overall remained cautious as participants awaited clearer economic signals for the year ahead. Overall, Q4 was characterized by a cautious and balanced market, with reduced demand and external economic factors influencing Neomycin Sulphate prices in Germany.
For the Quarter Ending September 2024
North America
In Q3 2024, the pricing landscape for Neomycin Sulphate in North America displayed a mixed trend, with the most pronounced fluctuations occurring in the U.S. market. Initially, prices experienced a decline, followed by a mid-quarter increase, only to decrease again as the quarter came to a close.
The initial price drop was influenced by several factors exerting downward pressure on the market. Recent economic data revealed a consistent decline in inflation over the past five months, which contrasted sharply with the rapid price increases seen earlier in the year. However, the middle of the quarter brought a surge in consumer confidence and an economic rebound, which significantly heightened demand for Neomycin Sulphate. This increased demand tightened the balance between supply and demand, leading to a temporary price rise. Concerns regarding potential supply chain disruptions, particularly related to port strikes and congestion at overseas ports, added to the urgency. Importers rushed to secure inventory, further exacerbating supply constraints and pushing prices upward. Additionally, early Christmas demand prompted retailers to engage in proactive stockpiling, which further tightened supply availability. Despite this brief uptick, prices faced another decline in September due to a combination of factors affecting both supply and demand dynamics. A notable decrease in new orders, driven by a general weakening in demand and growing political uncertainty surrounding the upcoming presidential election in November, led consumers to adopt a more cautious spending approach.
As the quarter concluded, Neomycin Sulphate was priced at USD 11,950 per metric ton (USP, FDA) CFR New York, reflecting the fluctuations and complexities of the market throughout the quarter.
Asia Pacific
In Q3 2024, the Neomycin sulphate market in the APAC region exhibited a varied pricing trend influenced by several key factors. At the beginning of the quarter, prices experienced a decline in July, primarily driven by sluggish consumption levels both domestically and internationally. The Chinese market, in particular, faced a downturn as demand weakened, exacerbated by limited support from downstream sectors. Additionally, rising freight costs, fueled by disruptions in global maritime traffic, significantly impeded international demand for Neomycin sulphate. As the quarter progressed, however, a shift in market dynamics occurred, leading to a rebound in prices. This upward trend was supported by robust demand from end-user industries, alongside effective inventory management strategies implemented by market participants. The global economic recovery efforts further bolstered this price increase, contributing to an overall positive outlook in the market. Despite this mid-quarter surge, prices began to decline again as the quarter came to a close, influenced by a confluence of adverse market dynamics. Insufficient demand became a key concern, marked by a noticeable drop in new orders, particularly in exports. The appreciation of the Chinese yuan against the USD also played a significant role, as it made exports more expensive for foreign buyers, thereby reducing foreign demand and applying additional downward pressure on prices.
Europe
In Q3 2024, the European market for Neomycin sulphate experienced a mixed pricing trend, shaped by a variety of interconnected factors. Initially, prices rose steadily through the first half of the quarter, buoyed by consistent demand from end-users, which laid a solid foundation for price growth. The easing of inflation in Germany, which dropped to 2% annually, also played a significant role in this upward momentum by alleviating some financial pressures on consumers. This decline in inflation enhanced consumer purchasing power, positively influencing the demand for pharmaceuticals, including Neomycin sulphate dihydrate. However, as September approached, a significant downturn began to manifest. A key factor contributing to this decline was a marked drop in demand, representing the steepest decrease seen in recent months. In response to this weakening demand, market participants moved quickly to adjust their pricing strategies, leading to widespread price reductions aimed at stimulating sales. This proactive response only served to accelerate the downward trend in Neomycin sulphate prices, creating a challenging environment for suppliers as they navigated the shifting market dynamics. Overall, the quarter was characterized by an initial period of growth followed by a sharp decline, reflecting the complex interplay of demand, consumer sentiment, and economic conditions across the European market.
